Krystal Biotech, Inc. (KRYS)
$321.16-3.29%Close
SELLBEAR · day 17
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $9.5B
- Beta
- 0.50
- P/E (TTM)
- 38.83
- Short % float
- 14.84%
- Days to cover
- 11.2
- SI change
- +9.9%
- 1W
- -1.73%
- 1M
- -5.55%
- vs SPY 1W
- -1.59%
- vs SPY 1M
- -8.06%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 53
- VALUE
- 31
- GROWTH
- 49
- GARP
- 57
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC11.6%
REV YoY-
ROE19.3%
EPS YoY-
ROA16.1%
GROSS93
OP45
NET55
[VALUATION]
P/E TTM38.83
P/E FWD39.07
SECTOR PE20.34
INDUSTRY PE13.84
P/B6.98
P/FCF-
EV/EBITDA41.13
EV/EBIT-
PEG1.60
FCF YIELD-
RISK
INT COV-
D/E0.65
ALTMAN Z-
CURR RATIO8.32
ND/EBITDA-
BETA0.50
Company news
FAQ
- What is LOPJLB’s current signal on KRYS?
- LOPJLB’s latest quantitative signal on Krystal Biotech, Inc. (KRYS) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is KRYS in?
- Krystal Biotech, Inc. (KRYS) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Krystal Biotech, Inc. (KRYS) do?
- Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several …